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Short Summary 
A study about using ICD-10-CM codes to identify chlamydia and gonorrhea cases found that 







Background: While researchers seek to use administrative health data to examine outcomes for 
individuals with sexually transmitted infections, the ICD-CM-10 codes used to identify persons 
with chlamydia and gonorrhea have not been validated. Objectives were to determine the validity 
of using ICD-10-CM codes to identify individuals with chlamydia and gonorrhea. 
Methods: We utilized data from electronic health records gathered from public and private health 
systems from October 1, 2015 to December 31, 2016. Patients were included if they were aged 13-
44 years and received either 1) laboratory testing for chlamydia or gonorrhea or 2) an ICD-10-CM 
diagnosis of chlamydia, gonorrhea, or an unspecified STI. To validate ICD-10-CM codes, we 
calculated positive and negative predictive values, sensitivity, and specificity based on the 
presence of a laboratory test result. We further examined the timing of clinical diagnosis relative 
to laboratory testing. 
Results: The positive predictive values for chlamydia, gonorrhea, and unspecified STI ICD-10-
CM codes were 87.6%, 85.0%, and 32.0%, respectively. Negative predictive values were high 
(>92%). Sensitivity for chlamydia diagnostic codes was 10.6% and gonorrhea was 9.7%. 
Specificity was 99.9% for both chlamydia and gonorrhea. The date of diagnosis occurred on or 
after the date of the laboratory result for 84.8% of persons with chlamydia, 91.9% for gonorrhea, 
and 23.5% for unspecified STI.  
Conclusions: Disease specific ICD-10-CM codes accurately identify persons with chlamydia and 
gonorrhea. However, low sensitivities suggest that most individuals could not be identified in 
administrative data alone without laboratory test results. 








Administrative data are routinely collected healthcare claims and service delivery data that 
detail diagnoses and procedures as well as medication prescriptions for populations that interface 
with the health system. These data are a convenient source for public health researchers to assess 
incidence1 and prevalence2,3, quality of healthcare4,5, health outcomes6,7, patient safety8, and 
econometrics9, areas of particular interest as STI services move away from STI clinics to primary 
care providers10. Researchers increasingly seek to leverage large administrative databases, such as 
all-payer claims databases, for population-level studies.  In these studies, specific health conditions 
or outcomes are typically identified using administrative data standards for clinical diagnoses, the 
International Classification of Diseases, Ninth and Tenth Revisions, Clinical Modification (ICD-
9-CM and ICD-10-CM) codes as laboratory test results are not available. Examples include an 
analysis of chlamydia surveillance in British Columbia11 as well as the Global Burden of Disease 
project12, which uses ICD codes to estimate incidence and burden of many diseases. 
Despite frequent use of ICD-9-CM and ICD-10-CM codes in studies, the validity of ICD 
codes for identification of conditions has not been well examined. While there exist studies which 
have tested the accuracy of ICD codes for conditions such as male infertility13, acute ischemic 
stroke 14, and pneumonia15, evidence of the accuracy of ICD codes for sexually transmitted 
infections (STIs) remains largely unexamined.  A recent systematic review16 found only two 
studies17,18 which assessed chlamydia and gonorrhea in the context of pelvic inflammatory disease 
(PID).  These two studies reported a wide range of positive predictive values from 56% to 100% 
and only assessed ICD-9-CM codes as they were conducted before October 1, 2015, the mandatory 







Our objectives for this study were to assess 1) validity of using ICD-10-CM diagnostic 
codes to identify persons with chlamydia and gonorrhea; and 2) the timing of provider’s ICD-10-
CM diagnosis in relation to availability of laboratory testing.  
MATERIALS AND METHODS 
Study Design and Setting 
We employed a retrospective cohort study of patients extracted from an existing STI testing 
registry from October 1, 2015 to December 31, 2016 described previously19. The registry consists 
of electronic health records (EHRs), including administrative and laboratory testing data, from the 
Indiana Network for Patient Care (INPC) linked to clinical (morbidity) and testing records from 
Indiana’s largest public health program of individuals tested for chlamydia, gonorrhea, or syphilis 
from January 1, 2004 to December 31, 2016.  Individuals were matched based on name, date of 
birth, social security number, race, and ethnicity. ICD-10-CM codes were only in INPC data 
whereas tests were contributed by both INPC and STI program data.   
The INPC20-22 is the nation’s oldest and most comprehensive community health 
information exchange (HIE). The HIE network connects over 100 health care facilities including 
hospitals, physicians’ practices, pharmacy networks, long-term post-acute care facilities, 
laboratories, and radiology centers across Indiana. The INPC is primarily used to support clinical 
care by making data available to clinicians, although it is also routinely used to support health 
services and public health research23.  
To evaluate whether ICD-10-CM codes for chlamydia and gonorrhea were valid, we 
compared ICD diagnoses from the INPC with laboratory testing data available from the STI testing 







Cohort Assembly and Data Extraction 
Because gonorrhea and chlamydia occurs most often among people at reproductive age24, 
our study focused on patients aged 13 to 44 years. Patients were included if they were between 13 
and 44 years old and either received an ICD-10-CM clinical diagnosis documented in their EHR 
or possessed a laboratory test result for chlamydia or gonorrhea. Individuals with unique episodes 
of care involving an ICD-10-CM code or positive laboratory result for an STI were classified as a 
case per usual public health surveillance practice. The ICD-10-CM codes utilized to identify STI 
cases were 1) chlamydia: A55, A56, A71, and A74.9; 2) gonorrhea: A54; and 3) unspecified STI: 
A64.  
Per CDC de-duplication case definition25, patients with multiple of the above ICD 
diagnoses for a given disease fewer than 30 days apart were defined as only one disease case. If a 
patient had multiple ICD diagnoses for a given disease >30 days apart, only the first disease case 
was selected and assessed for the study. Among patients with no documented ICD-10-CM 
diagnosis for chlamydia or gonorrhea during the study period but who possessed at least one 
positive laboratory test for one of these STIs, their first positive test result was selected and 
assessed for the study. Finally, among patients with no documented ICD-10-CM diagnosis for 
chlamydia or gonorrhea during the study period and who possessed no positive laboratory test 
result during the study period, their first negative test result was selected and assessed for the study. 
Cohorts for each group of ICD-10-CM codes were extracted from the registry based on 
inclusion criteria and de-duplication rules. For each case, we extracted the subject identifier, ICD-
10-CM diagnosis code, date of ICD diagnosis, laboratory test specimen collection date, and date 







Assessment of Testing for Cases Diagnosed with an STI 
We first assessed whether those cases involving an ICD-10-CM diagnosis for an STI also 
contained a laboratory test result for the same STI. Each case was linked with available laboratory 
test result(s) that were within 30 days of the date of ICD diagnosis. 
Validation of ICD-based STIs 
Case status was determined based on the combination of ICD-10-CM diagnosis plus 
laboratory test results. With respect to chlamydia and gonorrhea, true positive (TP) cases were 
defined as those with both a disease-specific ICD diagnosis and a corresponding positive 
laboratory test. False positive (FP) cases were defined as those with a disease-specific ICD 
diagnosis and a corresponding negative laboratory test. Individuals with a disease-specific ICD 
diagnosis without a corresponding laboratory test were removed from the ICD validation 
assessment as their disease status could not be confirmed. 
False negative (FN) cases were defined as individuals with a positive laboratory test result 
but no corresponding, disease-specific ICD diagnosis. True negative (TN) cases were defined as 
individuals with a negative laboratory test result and who did not have an ICD diagnosis. The 
algorithm to classify case status is depicted in Figure 1. 
For the assessment of cases involving the unspecified STI diagnostic code (A64), TP cases 
were defined as those with any STI positive laboratory test, STI tests are shown in Table 3. FP 
cases were defined as those with either all STI negative results or no laboratory test. We included 
unspecified STI cases with no laboratory test to determine if STI-related visual examinations may 
be documented in the medical chart. However, the chart review found no visual examinations were 







determined a priori whether a patient with a positive STI laboratory test would have either received 
an unspecified STI diagnosis or the corresponding STI-specific ICD code. TN cases were not 
classified as it cannot be determined whether a provider was testing for specific STIs or testing 
because the STI condition was unknown. 
Due to the potential number of STI tests within 30 days of an A64 diagnosis, the 
corresponding laboratory test(s) at a specific date was determined based on several criteria. First, 
if the A64 diagnosis date and laboratory test specimen collection or result date were matched, then 
the test on the specimen collection or result date was considered the corresponding laboratory test. 
Second, if a case had multiple specimen collection dates, the laboratory test with the collection 
date closest to the ICD diagnosis date was determined to be the corresponding laboratory test. 
Finally, if two laboratory tests had collection dates the same number of days from the date of the 
ICD diagnosis, but one specimen collection date is before and the other is after the date of 
diagnosis, the laboratory test with the collection date before the date of the ICD diagnosis was 
selected.  On the date of the corresponding laboratory test, multiple laboratory tests could be 
ordered. 
Medical Chart Reviews for Data Quality 
For data quality purposes, we conducted chart reviews to check whether ICD diagnoses or 
laboratory test results missing from designated fields in the EHR might be present in other parts 
of the patient record, such as physician notes. Chart reviews included all cases where the case 








 Additional chart reviews were conducted among 300 randomly selected cases with an ICD 
diagnosis of A64 as well as 300 cases with a positive laboratory test result for either STI but no 
disease-specific ICD diagnosis. No additional ICD diagnoses or laboratory test results were found 
during the chart reviews; therefore, all STI laboratory testing procedures and results were captured 
within each patient’s EHR. 
Assessment of Clinical Diagnosis Relevant to Laboratory Testing 
To assess provider ICD diagnostic behavior, we compared the date of the laboratory test 
result to the date of ICD diagnosis for those cases which possessed both an ICD diagnostic code 
and a laboratory test result. If a patient had multiple test result dates, the date closest to the ICD 
diagnosis date was selected. Further, if two dates had the same number of days from the date of 
the ICD diagnosis, but one test result date is before and the other is after the date of diagnosis, the 
test result date before the date of the ICD diagnosis was selected.   
Statistical Analyses 
Descriptive statistics were calculated to assess whether those cases with an ICD-10-CM 
diagnostic code possessed a corresponding laboratory test result within 30 days. The proportion of 
cases with a corresponding positive test, corresponding negative test, or missing laboratory testing 
information were calculated using only those cases with an ICD-10-CM diagnostic code. For 
patients with either positive or negative laboratory test results, using the case status definitions, we 
further calculated sensitivity, specificity, positive predictive value (PPV), and negative predictive 
value (NPV) for chlamydia and gonorrhea (disease-specific ICD cases). Sensitivity denotes the 
proportion of cases which are TP compared with all cases with disease. Specificity denotes the 







proportion of cases which are TP cases compared to cases with a disease-specific ICD diagnosis. 
NPV denotes the proportion of cases which are TN compared cases without a disease-specific ICD 
diagnosis. Confidence intervals were calculated by exact binomial method for each sensitivity, 
specificity, PPV, and NPV. For the unspecified STI cohort, because of the in-depth chart review 
process, we decided to only include those cases which were chart reviewed in the analysis. To 
provide unbiased estimates that are representative of the population of the INPC, all rates, 
estimates, and confidence intervals (95% CI) for the unspecified STI cohort were weighted based 
on the sampling methodology. 
To examine diagnosis dates relative to laboratory testing dates, we calculated the difference 
between the date of laboratory test result and the date of ICD diagnosis for TP and FP cases. 
Negative numbers indicate the date of diagnosis occurred before the laboratory result date, “0” 
indicates that the date of ICD diagnosis was the same as the laboratory result date, and positive 
numbers indicate the date of diagnosis occurred after the laboratory result date. All analyses were 
conducted using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). 
RESULTS 
Study Population 
Over an 18-month period, a total of 1,489,598 unique patients, between 13 and 44 years 
old, had at least one encounter in the INPC. Of these, a total of 238,876 individuals (16.0%) were 
either tested for chlamydia or gonorrhea, or diagnosed with an ICD-10-CM code of interest; 81,572 
patients received an ICD diagnosis or were tested for chlamydia, 79,640 for gonorrhea, and 603 








Assessment of Laboratory Testing for Cases Diagnosed with an STI 
Among these cohorts, 914 patients received an ICD diagnosis of chlamydia, 349 for 
gonorrhea, and 603 for an unspecified STI. Information on laboratory testing among those cases 
with an ICD-10-CM diagnosis is summarized in Table 1. The proportion of diagnosed chlamydia 
or gonorrhea cases with a corresponding positive laboratory test result was 81.9% and 78.2% 
respectively. Of unspecified STI cases, 32.0% possessed a corresponding positive laboratory test 
for any STI and 24.7% of cases possessed a corresponding positive laboratory test for chlamydia 
or gonorrhea. 
Validation of ICD-based STIs 
We identified 749 TP, 106 FP, 6306 FN, and 74,352 TN for chlamydia, 273 TP, 48 FP, 
2552 FN, and 76,739 TN cases for gonorrhea, and 193 TP and 410 FP cases for unspecified STI. 
All case statuses and validity measures are depicted in Table 2. Positive predictive values varied 
among each disease cohort with 87.6% for chlamydia, 85.0% for gonorrhea, and 32.0% for 
unspecified STI. Negative predictive values were high with 92.2% for chlamydia and 96.8% for 
gonorrhea. Sensitivities were low with 10.6% for chlamydia and 9.7% for gonorrhea. Specificities 
were 99.9% for both chlamydia and gonorrhea.  
A total of 603 patients received an ICD diagnosis of an unspecified STI. Just 1.3% (8/603) 
of these unspecified STI cases received a disease-specific ICD diagnosis in addition to the non-
specific STI diagnosis (4 chlamydia, 2 chlamydia and gonorrhea, and 2 bacterial vaginosis). The 
laboratory test combinations ordered by providers are summarized in Table 3. Only 32.0% 
(193/603) were found to have at least one corresponding positive laboratory test result. Among the 







respectively. Of the cases who received testing, only 21.5% (107/498) tested positive for 
chlamydia and 15.5% (76/490) for gonorrhea.  
Assessment of Clinical Diagnosis in Relation to Laboratory Testing 
Information on the date of STI diagnosis in relation to the date of laboratory test results is 
presented in Figure 2. The proportion of cases for which the date of diagnosis occurred on or after 
the date of laboratory result was 84.8% for chlamydia, 91.9% for gonorrhea, and 23.5% for 
unspecified STI.  When the date of ICD diagnosis for chlamydia or gonorrhea occurred at or after 
the date of laboratory result, the ICD diagnosis was more likely to be TP (98.4% and 91.9%, 
respectively).  When the date of ICD diagnosis for chlamydia or gonorrhea occurred prior to the 
date of laboratory result, the ICD diagnosis was more likely to be FP (89.5% and 92.3% FP, 
respectively).    
DISCUSSION 
Using a population-level cohort drawn from linked electronic health records with STI 
morbidity records, we found that most disease-specific ICD-10-CM codes for chlamydia and 
gonorrhea accurately identified clinically diagnosed patients. The PPVs observed in this study 
using retrospective chart review supports the use of disease-specific ICD-10-CM codes as a valid 
method to identify cases of chlamydia and gonorrhea for secondary analyses, including health 
services research. However, low sensitivities and patterns of the date of diagnosis occurring before 
the date of laboratory testing observed in this study warrant caution for those who desire to use 
ICD-10-CM codes to conduct chlamydia and gonorrhea-related health services research. 
Using a STI registry composed of electronic health records pooled from multiple health 







chlamydia and gonorrhea were 87.6% and 85.0%, respectively. The PPVs were likely affected by 
presumptive diagnoses by clinicians based on the comparison of ICD diagnosis dates to laboratory 
test result dates. Results showed that, especially among FP cases, some clinicians were diagnosing 
patients without a laboratory test or before the test results were available. However, the high rates 
of TP cases make ICD-10-CM codes a reasonable method to identify cases for those in public 
health programs who wish to examine STI treatment and outcomes. 
Sensitivities for both STIs examined were low: chlamydia 10.6% and gonorrhea 9.7%. This 
suggests low usage of ICD-10-CM codes by clinicians when STI cases were identified. Compared 
to the 1,215 STI cases that possessed an ICD-10-CM code, we identified 8,858 patients with a 
positive confirmatory laboratory test for an STI but no clinical diagnosis code in the medical 
record. While some cases were diagnosed in a public health clinic that does not bill third-parties 
for reimbursement, most cases were identified from records in private health care clinics, hospitals, 
or emergency departments. The high number of cases without an ICD diagnosis is likely due to 
screening efforts by clinicians to test young women (aged 16-24 years) for chlamydia, a Healthcare 
Effectiveness Data and Information Set (HEDIS) performance metric in the U.S.26 Additionally, 
another possible explanation could be that patients are receiving encounter-related ICD-10-CM 
codes (e.g. “general adult medical examination” or “encounter for gynecological examination") 
rather than clinical diagnosis codes. Therefore, using a diagnostic code only approach to estimate 
chlamydia and gonorrhea prevalence or incidence is likely to underestimate true prevalence or 
incidence of disease and thus should not be utilized for public health surveillance. Instead, public 
health authorities should use administrative data in combination with laboratory-based reporting, 
electronic systems where possible, for surveillance efforts which are generally required under state 







We further examined individuals who were diagnosed with the non-specific ICD-10-CM 
code for an STI (A64). The A64 code was found to have a low PPV of 32.0% with clinicians 
testing for 7 different STIs with 24 unique testing combinations. Although we identified some 
positive chlamydia and gonorrhea cases in this cohort, incorporating the A64 code with the specific 
ICD codes to identify cases will result in an overall lower PPV due to the number of FPs and other 
STIs potentially indicated by this code.  
This analysis has several limitations. The first is that specific codes may have been under-
utilized because specific diagnosis is usually made after the encounter, and treatment may not be 
associated with an ICD-10 code.  Second, some cases may have received an ICD diagnosis or a 
laboratory test result, but these data may have fallen outside of the end date of our data. Therefore, 
we may have misclassified some cases. However, based on our assessment of the time of ICD-10-
CM diagnosis compared to laboratory test result dates, the misclassification should be minimal. 
Third, we were unable to assess the added value of encounter-related ICD-10 codes, the effect of 
reason for visit, CPT codes or clinical location of the encounter because they were not available in 
our registry. Additionally, the study dates may have contributed to the low usage of disease-
specific ICD codes as clinicians may not have acclimated to utilizing ICD-10-CM codes which 
were implemented in the United States on October 15, 2015.  Finally, our findings might not be 
generalizable outside of Indiana given that all providers were in a single state, although we did 
utilize data from multiple health systems of variable size and complexity.  
To our knowledge, this is the first study which attempted to validate ICD-10-CM codes for 
identifying cases of chlamydia and gonorrhea. This study was conducted using a population-level 
cohort with EHR chart reviews from a large community-wide HIE network linked with records 







chart reviews of all patients in the INPC who had an ICD diagnosis of chlamydia or gonorrhea 
without positive laboratory test result, although true disease status could not be confirmed in all 
cases rather only in subset of sampled cases. 
In conclusion, there should be caution in using ICD-10-CM codes to identify cases of 
chlamydia or gonorrhea. Despite high PPVs for chlamydia and gonorrhea ICD-10-CM codes, these 
codes only identify a meager portion of patients with chlamydia or gonorrhea infection.  Accuracy 
of ICD-10-CM codes were further associated with whether the date of diagnosis was on or after 
the date of laboratory testing. In addition, an unspecified STI ICD-10 code might identify some 
chlamydia or gonorrhea cases, but its PPVs for chlamydia or gonorrhea infection were low.  Our 
results suggest that gonorrhea and chlamydia cases are better identified by laboratory test results 
alone or in combination with ICD-10-CM codes rather than only ICD-10 codes in administrative 
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Figure 1. Algorithm used to classify chlamydia and gonorrhea cases based on ICD-10-CM 
diagnosis and laboratory testing results. 
Figure 2. ICD-10-CM diagnosis dates compared to laboratory test result dates in days. Negative 


























Table 1. Chlamydia, gonorrhea, and unspecified STI laboratory test results by associated ICD 
diagnosis code. 
 
Laboratory Testing and Results 
ICD Diagnosis Positive 
(% among ICD) 
Negative 
(% among ICD) 
No Testing  
(% among ICD) 
Total 
Chlamydia 749 (81.9) 106 (11.6) 59 (6.5) 914 
Gonorrhea 273 (78.2) 48 (13.8) 28 (8.0) 349 
Unspecified STI (A64) 193 (32.0) 331 (54.9) 79 (13.1) 603 
Unspecified STI (A64) values are weighted for the sampling methodology. Laboratory+ indicates 
presence of a positive laboratory test. Laboratory tests used to determine laboratory testing for 









































81513 87.6                   
(87.6-
87.6) 
92.2                 
(92.2-
92.2) 
10.6                       
(10.6-
10.6) 









79612 85.0                  
(85.0-
85.1) 
96.8                 
(96.8-
96.8) 
9.7                       
(9.6-9.7) 










--- --- 603 32.0                   
(32.0-
32.1) 
--- --- --- 
Unspecified STI (A64) values are weighted for the sampling methodology. All 95% CI bounds 
were within 0.01% of the value. Laboratory tests used to determine TP and FP for unspecified 







Table 3. Combination of Lab Orders Associated with the Diagnosis of Unspecified STI (A64). 
































CT = Chlamydia; GC = Gonorrhea; SYPH = Syphilis; TRICH = Trichomoniasis; HERP = 
Herpes; Gard = Gardnerella vaginalis; CAND = Candidiasis 
AC
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